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ABSTRACT 
THERAPEUTIC TARGETING OF TUMOR ASSOCIATED MACROPHAGES 
Stephanie K. Watkins 
September 20, 2007 
Previous studies on the mechanistic induction of anti-tumor responses by IL-12 
cytokine therapy have focused on the adaptive immune response, specifically the 
activation NK cells and T cells as the primary targets of IL-12 treatment. In contrast, 
little attention has been given to the potential role of macrophages in the initiation of anti-
tumor responses by IL-12 therapy despite reports that macrophages playa major role in 
promoting tumor growth and metastasis and in suppressing anti-tumor immune responses. 
Based on the functional adaptivity hypothesis, which is the concept that macrophages 
functionally adapt, rather than differentiate into specific mature subsets, in response to 
environmental stimuli, we hypothesized that tumor infiltrating (TIMs) as well as tumor-
associated macrophages (TAMs) could be converted from tumor supportive activities to 
pro-immunogenic activities by IL-12 therapy. We examined the functional activities 
displayed by TIMs and TAMs after treatment with IL-12. Our data demonstrate (1) that 
tumor cells and tumor exosomes activate TIMs and TAMs by c:ell-contact dependent 
mechanisms involving ligation of CD40 and/or NKG2D, (2) that IL-12 treatment both in 
vivo and in vitro induces a rapid reduction of tumor supportive: activities and a 
concomitant increase in pro-inflammatory activities in TIMs as well as TAMs, (3) that 
VI 
IL-12 induces a rapid release of cytoplasmic IL-I5 from the in situ activated tumor 
associated macrophages and (4) the release of IL-I5 in essential to the recruitment of 
lymphocytes to the tumor and the metastatic lung, and to the destruction of the tumor and 
clearance of metastasis. It is concluded that macrophages in the tumor environment are 
activated and functionally modulated by the tumor. TIMs and TAMs respond to IL-12 
treatment by rapidly converting from suppressive, tumor supportive activities to 
inflammatory, pro-immunogenic activities. Tumor associated macrophages thus are a 
critical target of IL-12 therapy and may orchestrate the subsequent NK and T cell 
cytotoxic response against the tumor. 
Vll 





LIST OF FIGURES....................................................................... x 
INTRODUCTION....................................................................... 1 
Macrophage Activation and Plasticity................................ 1 
Tumor Associated Macrophages....................................... 5 
TAM Activation.............. .......... ...... ................ ................. 10 
TAM Plasticity and Cytokine Therapy.............................. 12 
Hypothesis, Significance, Summary... ........ ....................... 15 
MATERIALS AND METHODS........................................ ......... 18 
RESULTS................................................................................... 25 
Tumor Associated Macrophage Phenotype.................. ..... 25 
IL~ 12 Treatment in vitro Alters TAM Phenotype.... ... ....... 27 
IL-12 Treatment in vivo Alters TIM/TAM Phenotype...... 33 
IL-12 Induces TAM IL-15 Release.................................. 37 
TAMs Aid in IL-12 Induced Immuno-Activation............. 39 
Macrophages Activated by Tumor Exosomes........... ....... 47 
Tumors Activate Macs via CD40INKG2D Ligation......... 55 
CD40 Essential for Metastatic Growth............................ 63 
TAMs Stimulate Tumor Cells.......................................... 68 
Table 1. Tumor-macrophage interactions............. 73 
Vlll 
DISCUSSION........................................................................... 76 
Conclusions.... ........ ........................................................ 84 
REFERENCE LIST............................................................... 86 
CURRICULUM VITAE......................................................... 101 
IX 
LIST OF FIGURES 
FIGURE 
1. Macrophage functional diversity ............................................. . 
2. Tumor induced macrophage function .................................... .. 
3. IL-12 modulation of TAM function ....................................... .. 
4. TAM display the anti-inflammatory "suppressor"phenotype 
similar to tumor infiltrating macropahges ................................. .. 
5. IFNy restores CD 11 bhi Gr-l" phenotype ................................. . 
6. IFNy reduces TAM pro-tumorigenic cytokine production in 
response to LPS stimulation ..................................................... . 
7. IL-12 impact on TAM cytokine gene expression .................. . 
8. In vitro treatment alters cytokine gene expression .............. . 
9. IL-12 changes the pattern of cytokine production in vitro in 
response to LPS stimulation ................................................... .. 
10. In vivo IL-12 treatment induces a rapid shift in the cytokine 
profile that is sustained for at least 5 days .................................. .. 
11. In vivo injection ofIL-12 induces a rapid shift to 
pro-inflammatory functions systemically .................................... . 
12. IL-12 injection induces a decrease in pro-tumorigenic and an 
increase in pro-immunogenic cytokine genes ............................ .. 
13. TAMs release IL-15 in vivo in response to IL-12 treatment .. 
14. TAM cytoplasmic IL-15 is released rapidly as a bolus within 

















15. Neutralization of IL-15 reduces T cell infiltration in response 
to IL-12..................................................................................... 43 
16. Neutralizing IL-15 prevents IL-12 induced tumor destruction. 44 
17. Neutralization of IL-15 reduces T cell infiltration into 
metastatic tissue in response to IL-12 treatment.......................... 45 
18. IL-15 neutralization prevented the clearance of tumor 
metastasis in the lung.................................................................. 46 
19. IL-12 treatment prevents the formation or induces the break-
down of the major tumor blood vessel, which is prevented upon 
neutralization of IL-15........................ .................................. ..... 48 
20. Macrophages in beige mice respond to IL-12 treatment........ 50 
21. Depleting NK cells does not inhibit T cell infiltration in 
response to IL-12 induced IL-15 release................................. ... 51 
22. TAMs are actively producing cytokines upon ex vivo analysis. 53 
23. Unfiltered tumor supernatant activates macrophages..... ........ 54 
24. Tumor exosomes activate macrophages......... ............... ..... .... 56 
25. Tumor cells express CD40L and Rae-l and TAMs but not 
normal macrophages express elevated levels of surface CD40 and 
NKG2D receptors........................................................................ 57 
26. TAMs express elevated NKG2D mRNA gene expression....... 59 
27. CD40 and NKG2D are involved in macrophage activation 
by tumor exosomes........... ......... .................................................. 60 
28. Blockade of either NKG2D or CD40 ligation interferes with 
exosome activation of macrophages............ ................................. 61 
29. Anti-NKG2D Ab specifically blocks macrophage activation 
by exosome NKG2D ligation as shown rmNKG2D-Fc inhibited 
the ability of the blocking Ab to prevent cytokine production....... 62 
30. CD40 and NKG2D are involved in macrophage activation by 
tumor exosomes...... ... ............................................... ................... 64 
Xl 
31. Blocking Abs to NKG2D and CD154 do not inhibit 
macrophage cytokine production in response to LPS stimulation.. 65 
32. Cytokine secretion is decreased in TAMs from CD40-/- tumor 
bearing mice................................................................................. 66 
33. Tumor activated macrophage IL-15 release is blocked in the 
absence of CD40 and/or NKG2D ligation..................................... 67 
34. CD40-/- tumor bearing animals displayed reduced lung 
metastasis in comparison to tumor bearing wild type mice............. 69 
35. CD40-/- TAMs produce reduced levels ofMMP-9 and VEGF 
in comparison to wild type TAMs.................. .................. ............. 70 
36. Tumors grown in CD40-/- mice produced significant amounts 
of angiogenic factors MMP-9 and VEGF, although drastically 
less than tumors grown in wild type mice...................................... 71 
37. TAMs restore tumor expression of surface molecules ............. 72 
38. Tumor cytokines production induced by TAMs....................... 75 
xu 
INTRODUCTION 
Macrophage Activation and Plasticity 
Macrophages are important components of both innate and acquired immunity. 
They are highly heterogeneous, and have the ability to take on many phenotypes and 
functional properties. Macrophages are derived from circulating monocytes and either 
remain motile or take residence within tissues in the host where they exhibit tissue 
specific morphologies and distinct functional activities crucial for homeostasis of the 
tissue. Many of the behaviors that macrophages display could be considered opposing in 
nature, for example they can participate in pro-inflammatory or anti-inflammatory 
activities, be tissue destructive or tissue restorative and immunogenic or tolerigenic (Fig. 
1 )1, 2. Each of these diverse activities can be triggered by a variety of response modifiers 
such as cytokines, growth factors, hormones, arachidonates, stress hormones, PP ARS, 
F ABPs, etc. as well as by an activation signal received, such as TLR, CD40 and/or TNF-
R ligation 1-5. 
Macrophage activation traditionally refers to what is termed classical activation, 
or the pro-inflammatory, and phagocytic functions that macrophages employ during anti-
microbial immune responses. Macrophages are among the first cells to arrive at sites of 
infection. Infiltrating monocytes respond to tissue cytokines and chemokines to up 
regulate inflammatory activities. Upon activation macrophages increase expression of -1 
-1-
CD40 and/or TLR Ligation 
Cytokine mixture, ect. 
IL-4 <.. f\ ) IFNy 
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Figure 1. Macrophages are capable of many functions, many seeming opposing in nature, 
anti-inflammatory vs pro-inflammatory, and toxic vs healing. The function displayed is 
dependent upon the response modifiers encountered. Furthermore, macrophages will 
continue to differentially and reversibly adapt the functional profile displayed in response 
to progressive changes in the cytokine environment. 
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CD40 and TNF receptors, elevate production of pro-inflammatory cytokines, TNFu, IL 
and IL-6, and chemokines which recruit other immunological cells to the area. As the 
response progresses macrophages produce increased INOS and NO, participate in 
oxidative bursts and provide co-stimulation by the up-regulation of B7 and MHC class II 
molecules 1,3. At this point in the response, NK and T cells are present and producing 
IFNy. IFNy promotes the "generation" of the activated macrophage which is referred to 
as "classically activated" and displays enhanced pro-inflammatory and cytotoxic 
activities. 
In apparent opposition to the classically activated, pro-inflammatory functions, 
macrophages are also among the first cells to arrive at areas of non-infectious wounding, 
such as a muscle tear for example. In this situation, along with tissue macrophages they 
promote wound healing and tissue repair by the production of growth factors, proteases 
and angiogenic factors 3-5. Macrophages displaying wound healing or anti-inflammatory 
type profiles are described as being "alternatively activated." Alternative activation was 
first described by Siamon Gordon as macrophages activated in the presence ofIL-4 or IL-
13 3. Others have extended this description to refer to macrophages which display any 
pattern of function distinctly different from classically activated macrophages, and are 
found to produce anti-inflammatory cytokines, such as IL-I 0 and TGFp, as well as having 
increased arginase production 4-7. 
Many have tried to classify macrophages into distinct populations characterized 
by the state of activation or functional profile observed, for example classically or 
alternatively activated or based on the cytokines involved in the activation, Ml for 
cytokines typically involved in Thl responses and M2 for cytokines involved in Th2 
-3-
responses 5,7-10_ However, it is far too simplistic to suggest that macrophages are only 
classically (MI) or alternatively activated (M2) or exist in a polarized state between the 
two functional subsets. Macrophage activation is much more complex and can not be 
described in a linear fashion. Efficient macrophage activation requires at least two 
signals. One signal being a functional modulating signal, such as a cytokine, chemokine, 
hormone, etc. and the second being a stimulating signal such as TLR and/or CD40 
ligation or a mixture of cytokines 1,11. One example of macrophage plasticity can be 
observed by looking at a typical response to microbial infection. Once the bacteria have 
been cleared, macrophages begin to phagocytose apoptotic neutrophils and down regulate 
production of pro-inflammatory cytokines in favor of an up-regulation of tissue 
restorative functions 12-14. This situation provides a clear example of functional 
adaptivity rather than subset replacement. A second example presented by our lab 
demonstrates that upon activation the functional pattern displayed by macrophages 
depends on the nature of the stimulating ligand, the modulating stimulus encountered and 
the time points between when each signal was received and at what time point after 
activation or modulation the function was assayed 1_ When bone marrow derived 
macrophages were treated with IFNy for 24 hrs prior to LPS stimulation one pattern of 
function was observed, showing increased TNFu, IL-lP, and IL-12 production and 
decreased IL-l 0 and MCP-l production in comparision to bone marrow derived 
macrophages stimulated with LPS alone_ A second pattern of function that was distinctly 
different was then observed when the macrophages were treated with IL-4 instead of IFNy 
for 24 hrs prior to LPS stimulation, displaying increased TNFu, MCP-l, IL-12 and IL-6 
and decreased production oflL-l o. Additonally, other cytokine treatments prior to LPS 
-4-
continued to give different patterns of functions than observed from either IFN or IL-4 
treatment. In demonstration that timing of stimulation is important, different patterns of 
function were also observed when cytokine treatment (IFN, IL-4, etc.) and LPS 
stimulation was administered simultaneously. Moreover, we demonstrated that the 
pattern of function displayed continued to adapt with progressive changes to the cytokine 
environment 2, 11. These data established the functional adaptivity hypothesis, which 
states that macrophages are not subsets of stably differentiated cells, but rather they are 
plastic in nature and respond rapidly by changing their functional profile repeatedly as the 
response modifiers within the environment sequentially change 2, 11. 
Tumor Associated Macropbages 
The functional adaptivity hypothesis is applicable to many disease states which 
affect macrophage activation and functional profiles. One of the best examples of this is 
macrophage function and support of cancer. Macrophages have been observed to be 
associated with cancer for decades. However, their role in supporting tumor development 
has been largely unappreciated. Only recently have the observations that macrophage 
densities impact clinical outcomes become respected. 
Cancer progression and/or tumor development is highly dependent on the tumor 
cell's ability to interact with its surrounding stroma. Tumor stroma content can vary from 
model to model, however, most are found to contain high numbers of fibroblast, 
endothelial cells, and possibly most importantly, macrophages 6. High densities of tumor 
associated macrophages (TAMs) are reported to indicate a poor prognosis, specifically in 
-5-
models of breast, prostate, ovarian, and cervical cancers 15,16,17,18. Many studies have 
shown that macrophages are critical to tumor progression 6, 15, 19-24. In one example, Lin 
et al. have shown that depletion of macrophages in breast carcinoma delayed tumor 
progression and reduced metastasis 25,26. In another study, Nowicki et al. reported 
impaired tumor growth in CSF-I deficient mice, which are macrophage deficient, as 
CSF-I is required for differentiation ofmonocytes 16,27. The roles that macrophages play 
in tumor development are highly dependent on the tumor micro-environment 15,28. 
Tumors have been shown to actively recruit macrophages by the production of an array of 
chemokines and growth factors, most notably MCP-I and CSF-I 6,29,30. Tumors then 
seem to co-opt the normal role of macrophages to promote their development, invasion, 
and angiogenesis. Logically, macrophage recruitment to tumors should be 
immunologically beneficial to the rejection of the growing tumor. The tumor would be 
recognized as foreign due to tumor associated antigens (TAA) and normal macrophages 
would initiate an anti-tumor response, presenting T AA to T cells. However, the tumor 
micro environment is highly immuno-suppressive, therefore T AA are not being 
recognized and macrophage functions are being modulated toward pro-tumorigenic and 
immuno-suppressive functions by anti-inflammatory tumor produced metabolites, such as 
TGF~, VEGF, MMPs, and PGE2 (Fig. 2) 11,28,31-34. 
Of the many pro-tumorigenic functions that TAMs display, angiogenesis is one of 
the most important for tumor growth 35,36. Tumors require angiogenesis to grow beyond a 
certain size. Pollard has reported TAMs are responsible for "throwing the angiogenic 
switch" 15. TAMs contribute to angiogenesis by the production of essential factors, such 
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Figure 2. Macrophages which would otherwise be capable of promoting tumor 
destruction and cytotoxicity are influenced by metabolites of the tumor micro-
environment to promote tumor growth. Tumor growth is supported by macrophage 
production of cytokines and growth factors, which aid in angiogenesis, tumor migration, 
and immunosuppression. 
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understood. However, TAMs have been observed to cluster in areas of hypoxia. 
Hypoxia up-regulates the transcription factor, hypoxia-inducible factor 2-a (HIF-2a) in 
macrophages, which in tum induces VEGF expression. VEGF expression can then up 
regulate eSF-I, as well as act as a chemoattractant for further macrophage recruitment 25, 
35,36. Other molecules influencing angiogenesis include the production ofIL-I and 
increased eOX-2, both of which further increase HIF-Ia, inducing transcription ofVEGF 
26,37. MMPs, especially MMP -9 which is essential for the cleavage of biologically active 
VEGF, have also been shown to be up-regulated. According to reports studying tumor 
angiogenesis VEGF and MMPs are the most critical to vessel formation 26,37,38. 
Production of these factors, along with cytokine production of IL-I, IL-8, and TNFa, 
results in the proliferation and migration of endothelial cells, matrix remodeling, and the 
formation of blood vessels 15,35,39,40. 
In addition to angiogenic roles, TAMs are essential in other areas of tumor 
development as well, including metastasis, and immunosuppression. In metastatic 
development, macrophages infiltrate the basement membrane. This invasion along with 
the production of prot eases degrade the basement-membrane which creates a portal 
through which tumor cells can enter the stroma 31,36. The tumor cells are recruited to the 
portal by macrophage production of growth factors which serve as chemotactic molecules 
allowing tumor migration and metastatic spread 17,31. 
In immunosuppression, several populations of "suppressor" macrophages have 
been described. The first set described by Bordin in 1976, and further characterized by 
Mantovani, referred to TAMs which are recruited from circulating blood monocytes and 
are believed to be mature macrophages that have been polarized by tumor products. No 
-8-
distinct phenotype has been described for this population, however they are known to 
produce cytokines and growth factors favorable to tumor growth such as those previously 
mentioned 5,41. The second population described by Bronte and Gabriolovich is referred 
to as an immature myeloid suppressor (ImC) cell with a phenotype CD 11 b + IGRI + ICD31 +. 
They have been described to be able to "mature" to either a type I or type II polarized 
functional state depending on the cytokine treatment. However, this population has only 
been described in the tumor in the late stages of development, typically accumulating in 
the spleen and other lymph tissue 27,42-45. Gabriolovich reports that the ImC impair 
alloreactivity in vitro through a nitric oxide dependent mechanism and induces T cell 
apoptosis but require cell-cell contact 45,46. The third population is described as a mature 
myeloid cell by Rodriguez that accounts for high arginase I production and has a 
CDIIb+/GR-I" phenotype, but are also CDI6+ICD32+ and I-A/l-E+. Though the 
mechanisms are poorly understood, no cell-cell contact seems to be required for the 
inhibition of T cell activity by this popUlation. This population of TAMs are reported to 
display distinct morphology consisting of irregular cytoplasms with high intra-
cytoplasmic vacuoles and are low in phagocytic nature which makes their functional 
pattern unique from the other TAM populations reported 47. To date there has been no 
relationship described for between these three individually described populations, nor has 
there been a study addressing, at which time point during tumor development the 
different functional patterns are displayed by the TAMs. TAM function is known to vary 
based on the locations within or around the tumor, such as within perivascular sites, 
stromal regions, and hypoxic or necrotic areas, as well as in the metastatic tissue 35,36. 
Application of the functional adaptivity hypothesis may explain some of the discrepancies 
-9-
in deciphering these seemingly different TAM populations or TAMs functional profiles. 
The pattern of function displayed is influenced by the cytokines and growth factor 
components within the tissue micro environment. The levels of these metabolites change 
during tumor development and in different tumor micro environments (peri-vascular vs 
tumor parenchymal), these progressive changes would in turn cause the functional 
profiles of TAMs continue to shift. 
TAM activation 
All of the functional profiles that have been observed indicate that TAMs are 
actively producing cytokines, chemokines, and growth factors and contributing to tumor 
growth, suggesting that they are in some way activated. While it is known that tumor 
produced growth factors contribute to the continued modulation of TAM function 31,32,33, 
48, how TAMs actually become activated to elicit pro-tumorigenic functions remains to 
be determined. Some speculation includes activation by recognition of tumor associated 
antigens (T AA) or by the mixture of cytokines present with the tumor, but these 
speculations do not explain the activation of TAMs residing in tissues distal to the 
primary tumor mass. There are reports of tumor suppression mediated by the release of 
membrane vesicles or exosomes. Exosomes were first described in 1987 by Johnston 
while studying reticulocytes from sheep 49. Exosomes are formed by the inward budding 
of endosomal membranes, which are then referred to as multivesicular bodies, then are 
then secreted from endocytic compartments after fusing with the plasma membrane 50,51. 
Many cells have been shown to release exosomes including APes, epithelial cells, mast 
-10-
cells, and tumor cells. Exosomes are believed to function in two ways, first they are 
thought to eliminate obsolete proteins during cell maturation and secondly, they have 
been reported to communicate among cells by cell contact, participating in immune 
stimulation and immune suppression 52. Similarly, exosomes circulating in the tumor 
bearing host would interact with cells of the immune system allowing for both activation 
and suppression. NK cells, for example have been reported to be suppressed by 
interaction with the over-expression ofNKG2D ligands on the surface of tumor cells and 
tumor released exosomes 20,53,54. Further investigations of suppression reveal that tumor 
exosomes mediate CD8+ T cell apoptosis by Fas ligand 55. Stimulation by exosomes has 
been evidenced by the ability of DC derived exosomes to be able to effectively activate T 
cells in the absence of viable APCs 52. An exosome expresses the same receptors and 
ligands as the area of the cell membrane from which it was generated. Tumor cells 
express many surface molecules important in both suppression of cells of the immune 
system and for stimulation of tumor cell proliferation. Among the molecules reported are 
corresponding receptors and ligands which could theoretically allow for self stimulation 
such as, CD40/CD 154 and NKG2DlRae-1 20,53,56. Many other cells of the immune 
system also express these receptors or ligands, which provide them with activation 
signals. Macrophages express CD40 and be can efficiently activated by the ligation of 
CD40 by CD 154 12,57. It has not been examined as to whether tumor exosomes interact 
with tissue macrophages, which may provide some insight as to how macrophages distal 
to the tumor mass become activated TAMs and are induced to express pro-tumorigenic, 
pro-metastatic and anti-inflammatory activities. 
-11-
TAM Plasticity and Cytokine Therapies. 
There is evidence that TAMs are not a stable subset of pro-tumorigenic immuno-
suppressive cells, but rather their functional profile can change. Chu et al, have derived 
DCs from TAMs with IL-4 and GMCSF treatments and compared their ability to present 
Ag with DCs that were derived from peripheral blood monocytes of a healthy mouse. It 
was observed that DCs presenting T AA were capable of stimulating IFNy secretion by 
tumor specific T cells at the same level as, or in some cases higher levels than the 
peripheral blood monocyte derived DCs 58. Another example generated in our lab, 
showed that TAMs respond to IFNy treatment in vitro by reducing production of pro-
tumorigenic cytokines, MCP-l and IL-IO and increasing pro-inflammatory, TNFa and IL-
6 production in comparison to normal macrophages upon LPS stimulation II. These 
examples indicate that TAMs maintain functional plasticity and are capable of adapting 
their cytokine profiles in response to changes in environmental signals and/or stimulation. 
It is well established that tumor produces and inflicts its anti-inflammatory products on 
macrophages encouraging them to aid in tumor growth 15. However, observing TAM 
function after interrupting the tumor environmental signals, in other words testing their 
adaptivity, such as through cytokine treatments has not been examined. 
Cytokine therapies have previously focused on NK, NKT, and T cell responses 13, 
59-61 Much of the success has come from the administration of pro-inflammatory 
cytokines, such as IL-12 and or IL-2IIL-12. IL-12 is a heterodimeric molecule made up of 
an a chain, the p35 subunit, and a t~ chain, the p40 subunit. The subunits are linked by a 
disulfide bridge, which forms the biologically active heterodimer 14,62. IL-12 plays an 
-12-
essential role in interactions between the innate and adaptive responses. It is produced by 
macrophages, DCs, B cells, and possibly other accessory cells 14,62. IL-12 activates T 
cell and NK cells proliferation and production of IF Ny. IL-12 was fIrst shown to induce 
anti-tumor effects by Brunda et. al. 13. They reported that the potent anti-tumor effects 
were based on the induction ofIFNy and the activation ofNK and CD8+ T cells 13,14,63,64. 
Since then there have been many studies further supporting IL-12 anti-tumor activity in 
various tumor models, including melanomas, colon cancers, and mammary carcinomas 60, 
65. In addition to effector cell activation IL-12 has been shown to possess potent anti-
angiogenic capabilities and can inhibit growth factor production. Even in light of the 
many beneficial anti-tumor effects ofIL-12, there have been severe difficulties with 
clinical trials due to considerable toxicity when administered systemically. Hill and 
Egilmez, as well as many others have developed methods of administration to overcome 
clinical toxicity by encapSUlating IL-12 in lipid micro spheres or nanovessicals, alone or 
with other cytokines such as IL-2 and GMCSF in the treatment regime 23,61,66,67. This 
method allows for both local delivery as well as for a slow release of the cytokines, 
enabling the initiation of an effective response, while minimizing side effects and toxicity 
61,66. Hill et al. showed significant results in that IL-12 and GMCSF delivered in 
microspheres greatly reduced tumor proliferation, metastasis, and recurrence, and 
ultimately enhancing survival by 60% 61. The study showed that the anti-tumor effect 
was IFNy mediated and required a NK and NKT cell response as well as a long term, 
tumor specific adaptive T cell response 23,61,66. Trinchieri et al. confirmed the findings 
of Hill, and showed that the effectiveness of IL-12 therapy is IFNy mediated through the 
induction of CXC chemokines, such as IP-I 0 and MIG 60,68. 
-13-
Other pro-inflammatory cytokines, such as IL-18 and most impressively IL-15 
have been reported to act synergistically with IL-12, further enhancing anti-tumor 
responses 69,70. IL-15 was identified by its structural and physiological similarities to IL-
2 and by its ability to stimulate proliferation ofthe IL-2 dependent CTLL-2 T cell line in 
the presence of neutralizing Abs to IL-2 2,71. Much is still unknown of the synthesis and 
release ofIL-15, however, it is known to activate through one or a combination of its 
receptors, IL-15Ra,p,or y in soluble or, most often, a membrane bound form 71,72. IL-15 is 
produced by many cell types including skeletal muscle, BM stromal cells, thymic 
epithelia, heart, lung, and monocytes and macrophages. Monocytes and macrophages 
were the first cell types to be reported as a functionally relevant source of IL-15 in the 
context of the immune response 71. IL-15 has an essential role in the development and 
activation of many immune cells 73-75. IL-15 is required for NK cell development as is 
demonstrated by the absence ofNK cells in mice deficient in IL-15, IL-15R, and/or in the 
J AK3 and ST A T5 signaling pathways, which are required for IL-15 production or 
signaling by IL-15R 76,77. Furthermore, IL-15 is essential for NK proliferation, 
cytotoxicity, and cytokine production, as well as for NKimacrophage interactions 71,72,78. 
In addition to NK cells IL-15 is also essential to chemotaxis, proliferation, production of 
cytokines, protection from apoptosis and for cytotoxicity in T cells 79-81. Again, mice 
deficient in IL-15 or IL-15R lack functional CD8+ T cells and have minimal reactive 
CD4+ T cells 75,81,82. In the context of cancer, it was recently discovered that IL-15 could 
rescue tumor suppressed CD8+ T cells, allowing for enhanced survival 79,81,83,84. This 
revelation may be a key in understanding the mechanisms by which cytokine therapies 
may be improved to be more effective. 
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Hypothesis, Significance, and Summary. 
To date, all studies regarding cytokine therapies have focused on the adaptive 
anti-tumor response generated 6 or more days after treatment 61,85,86. However, the initial 
events from hours to several days following treatment have been ignored. The early 
events of cytokine therapy are likely to induce the production and/or release of other 
cytokines, such as IL-18 and/or IL-15 which would act synergistically with the 
administered cytokine in promoting the later observed adaptive response. It is unlikely 
that the potent adaptive anti-tumor response could take place without first reducing the 
highly immuno-suppressive influence of the tumor environment. In realization of this 
some studies have tried to circumvent the suppressive tumor environment by surgically 
removing the primary tumor mass prior to administering cytokine treatment 61. 
While the effects of removing the primary tumor mass would be beneficial, we 
hypothesize that the disruption of the apparent tumor, macrophage relationship may 
provide the needed window of opportunity for the activation and promotion of the 
adaptive anti-tumor response. Although, macrophages are not activated by IL-12, they 
are responsive in so far as their functional profile is modulated by JL-12. Given the 
elevated production of pro-tumorigenic cytokines and growth factors observed to be 
produced in the tumor bearing host, we furthermore hypothesize that TAMs are activated 
in a tumor-supportive fashion in situ, but will adapt their function to a more pro-
immunogenic profile in response to IL-12 treatment (Fig.3). 
In this study, macrophage activation by NK interactions, as well as by soluble 
tumor produced molecules, tumor cells and tumor exosome interactions were examined, 
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before and after IL-12 treatment. Macrophages were observed to be activated by cell-cell 
contact with tumor cells and/or tumor exosomes, which was prevented by the blockade of 
either CD40 or NKG2D ligation. Activated TAMs rapidly responded to IL-12 treatment 
by increasing pro-inflammatory cytokine production and releasing their intracellular store 
ofIL-15. The release ofIL-15 was observed to mediate infiltration ofCD4+ and CD8+ T 
cells into the tumor mass and metastatic lung. Furthermore, IL-15 release and 
lymphocyte infiltration coincided with tumor destruction and metastatic clearance. The 
observations made in this study provide insight as to the tumor/TAM relationship and on 
the impact of IL-12 treatment in the adaptation of the TAM functional profile in vitro and 
in vivo, which may contribute to the promotion of the anti-tumor response and ultimately 
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Figure 3. TAMs are modulated by IL-12 treatment to increase inflammatory cytokine 
production and release of IL-12, IL-18, and IL-15. The inflammatory cytokines then 
work synergistically with the IL-12 treatment to rescue and activate tumor suppressed 
NK, NKT cells and to promote the expansion and survival of CD8+ T cells. The 
motivated cells and enhanced effector functions promote cytotoxicity and tumor 
destruction. 
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MATERIALS AND METHODS 
Animals. C57Bl/6J, C57B1I6J _CD40tmIKiklJ, C57B1I6J-Lystbg-T, and DBAJ2J female mice 
were obtained from Jackson Laboratories. C57BLl6J-IL-15KO mice were obtained from 
Taconic Farms. All animal protocols received prior approval of the Institutional Animal 
Care and Use Committee and all experiments were performed in accordance with relevant 
guidelines and regulations. 
Tumor models. Lewis Lung carcinoma (3LLC) transfected to express membrane human 
Muc-l was obtained from Dr. Gordon Ross, Brown Cancer Center, Louisville, KY. TC-l, 
B16Fl, and LL-2 tumor lines were purchased from ATCC. Tumors were maintained by 
in vivo passage with limited intermittent culture in vitro. Tumor cells were injected s.c. 
in the left side of C57BLl6J mice. Tumors were measured at 3 day intervals with calipers 
at two bisecting diameters and an approximate volume is calculated by the formula (0.4) 
x (large diameter) x (small diameterf . Tumors were excised at 0.4-0.6 cc, diced and 
passed through a sieve (Bellco, Vineland NJ). The cells were washed with Dulbecco's 
PBS + 2% FBS and cultured for 2-:5 3 day cycles in RPMI1640 with 5% FBS, HEPES, 
and gentamycin before re-passage in vivo. Tumors with necrosis or with volumes 
twofold higher or lower than the mean of the group of mice were not used as a source of 
tissue for that experiment. 
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Macrophages. Macrophages were purified from single cell suspensions of lung, spleen, 
peritoneal lavage, and tumor mass of tumor bearing animals by magnetic bead separation 
using first a negative selection with anti-CDl9 and anti-CD5 and then positive selection 
with anti-CDllb (Mac-I) (Miltenyi Biotech, Auburn CA). The lungs and tumors were 
excised after perfusion with PBS-EDTA and removal ofthe mediastinal lymph nodes. 
Samples were treated with collagenase and DNase (Sigma) in 37° water bath for 30 min. 
Dispersed cells were then centrifuged over a discontinuous 30/35/45/70% percoll 
gradient. Macrophages were purified by magnetic bead separation from the cells banding 
at the 45/70% interface. Purity of>95% CDl1b+ 1 F480 was confirmed by flow 
cytometry for all 4 macrophage populations. Macrophages were cultured in RPMI1640 
supplemented with 5% fetal calf serum, HEPES, and gentamycin and were activated by 
addition of 100 ng/ml LPS where indicated. 
NK cell isolation. NK cells were purified from single cell suspensions of the spleen from 
normal animals by magnetic bead selection using the DX5 magnetic beads and columns 
from Miltenyi Biotech. 
Exosomes. Tumor exosomes were purified by magnetic bead selection. Tumor 
supernatants from cultures of adherent tumor cells were collected and centrifuged at 1500 
rpm for 10 min. to remove any detached intact tumor cells. 4p.g of biotinylated anti-
BCP8 (MUC-l) was added to 5ml of tumor supernatant for 15 minutes at room 
temperature. Anti-biotin magnetic beads (Miltenyi Biotech) were then added to the 
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supernatant for an additional 15 minutes at room temperature. Exosomes were then 
positively selected for using Macs columns (Miltenyi Biotech, Auburn CA). 
In vitro Cytokine treatment. Macrophages were plated at 1x105/ml in a 96 well plate 
for cytokine analysis or a 6 well plate for flow cytometric analysis. rm-IFNy was added to 
cultures at 20 ulml and soluble rm-IL-12 was added to cultures at 5 ng/ml. Cultures were 
incubated from 17- 48 hrs as indicated. 
In vivo IL-12 treatment. Interleukin-I2 containing micro spheres were prepared by 
phase inversion nanoencapsulation and supplied by Dr. Nejat Egilmez, State University, 
Buffalo NY 61,66,67. Microspheres were re-suspended at Img/IOOj.l1 in PBS for injection 
into the center of the tumor mass. 
Flow Cytometry. Cells were treated at Ij.lg/106 cells with Fc block (Pharmingen) for 15 
minutes in the presence of 0.1 % azide and 3% heat-inactivated fetal bovine serum 
(staining buffer). The cells were then incubated with fluorochrome conjugated antibodies 
at appropriate dilutions in staining buffer for 30 minutes on ice, washed and analyzed on 
a B-D FacsCalibur. Typically 10,000-20,000 cells were analyzed for their expression of 
surface proteins. Antibodies reactive with MAC-I, CD40, CDI54, CD44, H2Kb, Gr-1, 
F480, CD69, CD45, CD8, CD4, CD3, IL-I5RJ3, and NK1.1 were purchased from BD 
Pharmingen, anti-CD3I4 (NKG2D/CX5) was purchased from Biolegend, anti-hMuc-l 
(BCP8) provided by JUll Yan, Brown Cancer Center, Louisville, KY, and pan-specific 
anti-Rae-1 was purchased from R&D Systems. Intracellular IL-15 was assayed using the 
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BD Pharmingen cytofix/cytoperm kit per manufacturer's instruction along with the 
biotinylated goat anti-mouse IgG IL-15 antibody (R&D Systems) with a secondary 
streptavadin Ab (BD Pharmingen). Un-labeled anti-IL-15 (Novus Biochemicals) was 
used as an Ab control for intracellular staining. Appropriate isotype controls were ran for 
each Ab used. 
SuperArrray. For the GEArray cells were purified and lysed in Trizol for a cholorform 
extraction. Briefly 200~1 of choloroform was added to celllysates and centrifuged. The 
aqueous phase was collected and an equal amount of(25:24:1) phenol: choloroform: 
isoamyl alcohol was added and centrifuged. The aqueous phase was collected and 
washed with isopropanol, centrifuged and was with ice-cold 75% ethanol. After 
centrifugation the pellet was air dried, then resuspended in nuclease-free water for further 
purification by Qiagen Mini Elute RNA easy clean-up kit according to the manufacturer's 
instructions. The GEArray was then run according to manufacturer's instructions using 
3~g purified RNA. Data was analyzed by software provided by SuperArray for the 
GEArray Q series kit (software available on SuperArray website www.Superarray.com). 
Quantitative Real Time peR. cDNA was produced from mRNA from 106 cells from 
independent cell culture experiments (in treated and untreated tumor bearing and normal 
mice) by using t-LMACSTM One-Step cDNA kit (Miltenyi Biotec). The cDNA was used 
for quantitative real-time polymerase chain reaction (PCR) amplification with Sybr Green 
using gene specific primers for MIF (Superarray), TGF~, IL-15, and IL-18 (Maxim), and 
Klrk-1 (NKG2D) (Qiagen). Duplicate cDNA template samples were amplified and 
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analyzed in the MJ Opticon thermal cycler with conditions of 96°C for 15 min followed 
by 40 cycles of 95°C for 30 sec, 58°C for 30 s and 30 s at 72 with a plate read for gene 
expression between each cycle. A standard curve of cycle thresholds using 10 fold serial 
dilutions of cDNA samples was established and used to calculate the relative abundance 
of the target gene of each cytokine and vehicle control samples. Samples were run 
according to manufactures protocol and analyzed as fold increases or decreases between 
normal and tumor bearing animals after normalization to a J3-actin control. Differences 
between groups were analyzed using the REST program. 
Cytokine Analysis. Cytokines were assayed using Becton-Dickinson's cytokine bead 
array kit and a BD FacsCalibur according to manufacturer's instructions. Sample 
supernatants were analyzed undiluted and also at a 1 :50 dilution. ELISAs for TGFb, 
VEGF, and MMP-9 were performed using the Quantikine kits from R&D Systems, as per 
manufacture's instructions. The IL-15 ELISA was performed using rat anti-mouse IgG2a 
IL-15 Ab (R&D Systems) at 4mg/ml as the capture Ab in combination with the 
biotinylated goat anti-mouse IgG IL-15 antibody (R&D Systems) at 400 ng/ml as the 
detection Ab. 
Blocking Abs for in vivo studies. Neutralizing anti-IL-15 and IgG isotype control was 
obtained from eBioscience. Anti-IL-15 or the isotype control was injected i.p. At 500 ng 
1 hr prior to intra-tumor IL-12 microsphere treatment. Anti-NKI.l was obtained from 
BD Pharrningen and injected at 250 ng 24 hrs prior to IL-12 microsphere treatment. 
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Blocking Abs for in vitro studies. Anti-NKG2D (R&D Systems) was added to 
macrophages in vitro at 2~g/ml, 5~g/ml, or lO~g/ml to block NKG2D ligation. To 
measure specificity ofthe blocking anti-NKG2D, Fc-rmNKG2D purchased from R&D 
systems was added to cultures at 1,2,5, or 10 ~m1ml. Anti-CD154 (Biolegend) was 
added to 3LLC cells and exosomes with and without macrophages in vitro at 5~g/ml, 
lO~g/ml, or 25~g/ml to block the tumor cell ligation of macrophage CD40. 
Infiltration Studies. Mice were injected with 3LLC tumor cells subcutaneously, when 
the tumor measured O.5cc anti-IL-15 or anti-NK1.1 were injected 1 hr and 24 hrs prior to 
IL-12 microsphere injection respectively. Three and 5 days post treatment tissues were 
harvested. Mice were purfused with 10ml cold PBS, and the tumor mass and lungs were 
removed. Tumor diameter was recorded as previously mentioned. Wet weights ofthe 
tumor were recorded and digital images were obtained. The tissues were then pressed 
between frosted slides to acquire single cell suspensions. Cell populations were then 
stained for flow cytometric analysis. 
Histology. Animals bearing tumors were purfused with 10 ml PBS prior to lung 
extraction. The lungs were then harvested and kept in individual cassettes which were 
placed in 10% buffered formalin for 16 hours, washed in 70% EtOH and taken to 
University of Louisville School of Medicine, Pathology Department, (Louisville KY) DJr 
sectioning and H&E staining. 
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Digital Images. Digital images of the slides obtained from pathology services were taken 
with a Nikon coolpix digital camera at lOx magnification on a microscope. Slides were 
also scanned on a HP scanner unmagnified to count visible metastatic nodes. 
Statistical analysis. For flow cytometric analysis of the neutralization of IL-15 or 
depletion ofNK cell studies, the mean and standard deviation was calculated on the 
number of infiltrating CD4+/CD45+ and CD8+/CD45+ cells per lx106 tumor cells or 
lx106 viable lung cells recorded from 5 mice or 3 mice respectively. The significance 
between groups (5 individual mice/group) for cytokine production assayed by ELISA, 




Tumor associated macrophages display an anti-inflammatory CDllb+/Gr-l+ 
phenotype that shifts in response to inflammatory cytokine treatment. 
An accwnulation of myeloid or macrophage suppressor cells have been observed 
in many tissues of twnor bearing hosts. The cells are characterized by a CD 11 b + /Gr-l + 
phenotype and are thought to be contribute significantly to the suppression of the immune 
response by the production of anti-inflammatory or pro-twnorigenic cytokines. Primarily 
these cells have been reported to originate from the bone marrow and infiltrate tissues 
such as the spleen, liver, and lung and aid in metastatic development as well as immune 
suppression 19, 35, 43, 87. To determine whether resident macrophages from the peritonewn 
of tumor burdened animals displayed the anti-inflammatory, "suppressor" phenotype, 
macrophages were purified from twnor-bearing or healthy mice. The cells were then 
stained with anti-CDllb and anti-Gr-l (LY6G/C) fluorescent antibodies for flow 
cytometry analysis. The surface phenotype of macrophages from the twnor bearing 
animals display a shift from CD 11 bHi to CD 11 bLow in comparison to normal peritoneal 
macrophages. Concurrent with the shift in CD 11 b expression, approximately half of the 
CD 11 b + TAM population also expressed the Gr-l + phenotype (Fig 4.). Similarly TAMs 
purified from the spleen and lung of twnor mice also displayed an increase in Gr-l 
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Figure 4. Tumor associated macrophages display the anti-inflammatory "suppressor" 
phenotype similar to tumor infiltrating macrophages. Macrophages from tumor bearing 
and normal mice were enriched from the a) peritoneum, b) spleen, and c) lungs and 
stained for cell surface expression ofCDllb and Gr-l (Ly6G/C). Results are 
representative of three independent trials. 
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expression. Macrophages however, are known to have transient phenotypes and change 
functions due to changes in the micro-environment 1,2, 11. Therefore to determine if the 
phenotype of these macrophages was stable, TAMs were treated in vitro with pro-
inflammatory cytokine IFNy (Fig. 5) for 24 hours. Subequent flow cytometric analysis 
revealed that the Gr-I + expression receded and the CD 11 bHi phenotype was restored (Fig. 
5) 
In addition to their distinctive surface phenotype it has been reported and we have 
confirmed that, TAMs produce elevated levels of pro-tumorigenic cytokines, such as 
MCP-I and TGFp in response to LPS stimulation in comparison to normal macrophages 
from the peritoneum. (Fig.6). Treatment overnight with IFNy prior to LPS stimulation 
reduced pro-tumorigenic cytokines production (Fig.6) 
IL-12 treatment in vitro alters the functional profile of TIMs and TAMs. 
While IFNy treatment overnight is effective for altering macrophage function in 
vitro, pro-inflammatory cytokines, such as IL-12 have been shown to induce an anti-
tumor response with less toxicity when delivered locally to the tumor 61,66,67. To gain a 
broader perspective of the differences in cytokine gene expression between normal 
macrophages and TAMs and to define the impact of IL-I2 treatment, macrophages were 
isolated from the peritoneal cavity of normal and tumor bearing mice and cultured 
overnight with or without IL-12. SuperArray analysis indicated that many cytokine genes 
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Figure 5. IFNy treatment restores CD 11 bhi, Or-l- phenotype. Macrophage were purified 
from peritoneal lavage of normal or tumor bearing mice and stained for cell surface 
expression of CD 11 b and Or-I before and after overnight culture with 20 ufm1 IFNy. 
Results are representative of 4 independent trials. 
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Figure 6. IFNy reduces TAM production of pro-tumorigenic cytokines in response to 
LPS stimulation. M<1>s were purified from normal or tumor bearing mice and 
immediately or after overnight culture with 20 u/ml IFNy stimulated with LPS. 
Supernatants were then harvested and analyzed for cytokine production by ELISA. Data 
expressed as mean ± s.d. of triplicate cultures. * p <0.05, comparing groups normal vs 
TAM and TAM vs TAM + IFNy. Data are representative of3 independent trials. 
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receptor and chemokine genes. Other genes such as, MIF, IL-I0 and CCR2, which are 
products known to aid in tumor development were greatly up-regulated in TAMs 
compared to normal macrophages (Fig. 7a). Overnight treatment with IL-I2 appeared to 
enhance expression of the genes that were down-regulated in TAMs and simultaneously 
reduced the expression of the genes that were up-regulated in TAMs (Fig. 7b). Based on 
the results of this assay two pro-tumorigenic cytokines genes of interest, TGFp and MIF, 
that were found to be significantly up-regulated by the presence of the tumor and a pro-
inflammatory cytokine gene of interest, IL-I5 that were found to be up-regulated by IL-
12 treatment of TAMs by the superarray (Fig. 7b) were selected for quantitative analysis 
by real time qrt-PCR. TAMs expmssed a greater than 9-fold increase in expression of 
TGFp and MIF mRNA but very little IL-I5 or IL-I8 mRNA compared to normal 
peritoneal macrophages (Fig.8). Overnight culture with IL-I2 reduced the expression of 
both TGFp and MIF genes to near background levels and induced a 3-fold increase in 
expression of IL-I8 mRNA and a 20-fold increase in expression of IL-I5 mRNA (Fig.8). 
Given the vast differences in gene expression we then analyzed the pattern of 
cytokine production elicited by activation in vitro, the tumor infiltrating (TIMs) and 
peritoneal, splenic or lung TAMs were stimulated with 100ng/ml LPS immediately ex 
vivo or after overnight culture with rIL-I2. IL-12 treatment reduced or abrogated MCP-I 
production and elevated TNFa and IL-6 production by TIMs as well as by peritoneal, 
splenic and lung TAMs (Fig.9). The IL-I2 treatment reduced IL-IO production by splenic 
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Figure 7. IL-12 impact on cytokine gene expression of TAMs. Peritoneal Met> from 
normal or tumor-bearing mice (a) or from tumor bearing mice treated with placebo or 
IL-12 micro spheres (b) were analyzed by Superarray for expression of cytokine cytokine 
receptor or chemokine mRNA. Results shown are from a single gene array, however 
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Figure 8. In vitro treatment alters the cytokilne gene expression pattern. Macrophages 
were purified from peritoneal lavage of tumor bearing and normal mice and cultured 
overnight in the presence or absence of5 ng/ml IL-12. RNA was extracted and analyzed 
for expression ofTGF~, MIF, IL-15 and IL··18 by qrt-PCR. Data are expressed as 1 pg 
mRNA /106 cells ± s.d. of3 mice, * p <0.001 between normal macrophages and TAM or 
between TAM and TAM + IL-12. Data represent 4 independent trials. 
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Therefore, for each tissue analyzed, IL-12 treatment altered the pattern of the cytokine 
response to LPS stimulation. 
IL-12 treatment in vivo alters the functional profile of TIMs and TAMs. 
IL-12 effectively modified macrophage cytokine production in vitro, but to 
determine if IL-12 could alter the function of TAMs in vivo, mice bearing subcutaneous 
3LLC tumors were treated with IL-12 encapsulated microspheres. Peritoneal 
macrophages were harvested from 90 min to 5 days post injection and assayed for 
cytokine production following LPS stimulation. IL-12 treatment induced a dramatic shift 
in cytokine production in the peritoneal TAMs as early as 90 minutes after treatment (Fig. 
10). The elevated production of MCP-l and IL-I0 elicited from peritoneal TAMs from 
the placebo-treated tumor-bearing mice was reduced 2-3 fold in TAMs from the IL-12 
treated mice. Furthermore the production ofTNFa was observed to be elevated in TAMs 
following IL-12 treatment. This shift in funetional profile was sustained for at least 5 days 
after IL-12 treatment (Fig. 10). Purified IWlg and splenic TAMS (Fig. lla) displayed the 
same shift in their functional profile as peritoneal TAMs after injection of the IL-12 
microspheres. TAMs from spleen and lung displayed elevated production of MCP-l and 
IL-I0 and decreased production of IL-6 relative to normal controls. Three hours after IL-
12 treatment, the splenic and lung TAMs displayed a 3-fold or greater reduction in MCP-
1 and IL-l 0 production in response to LPS stimulation in vitro and a comparable increase 
in TNFa and IL-6 production (Fig. lla). Pmified TIMs from IL-12 treated mice displayed 
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Figure 9. IL-12 changes the pattern of cytokine production by TIMs and TAMs in vitro in 
response to LPS stimulation. Macrophages were purified from a) the tumor, b) peritoneal 
lavage, c) spleen, and d) lung tissue of normal or tumor bearing mice. The cell cultures 
were stimulated with 100ng/ml LPS immediately or after overnight culture with 5ng/ml 
IL-12. The culture supernatants were collected and analyzed for cytokines by CBA. Data 
are displayed as mean ± s.d. of macrophages from 3 mice, * p <0.05, ** P <0.01. Groups 
compare normal vs TAM and TAM vs TAM + IL-12. n.d. = none detected. The results 
are representative of four independent trials. 
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Figure 10. In vivo IL-12 treatment induces a rapid shift in the cytokine profile that is 
sustained for at least 5 days. Peritoneal M<I>s were purified 90 min to 12 hrs after 
injection ofIL-12 micro spheres subcutaneously (normal mice) or into the tumor mass. 
The M<I>s were stimulated with lOOng/ml LPS and the supernatant collected17 hrs later 
for cytokine analysis. Data is displayed as mean + s.d. of3 mice. *p<0.05. **p<O.Ol. 








Nannal + IL-12 
TAMs+IL-12 
a. 
r '00, I n.d lung J** 10...- ]** ,.-... 
.. :::;;:--]* 
--:r- j:' '~I '1 
.. * 
o 200 400 600 0 200 400 600 0 




TIMs FIiiiliiiiiilliiIl;lli1;f1~ In d --:JTlM m J **n.d TIMs + IL-12 _ 1-. _~----,_~_-.J 
o 4 6 0 100 200 300 0 250 500 750 






TlMI; TIMI , J •• 
0 4 
nglmllL-6 
Figure 11. In vivo injection of IL-I2 induces a rapid shift to pro-inflammatory functions 
systemically. a) Lung and splenic or b) tumor infiltrating M<l>s were purified 3 hrs after 
IL-12 injection. The cells were stimulated with LPS and the supernatant collected 17 hrs 
later for cytokine analysis. Data is displayed as mean ± s.d. of 3 mice per group. 
*indicates p<O.OS. **indicates p<O.OI. n.d. = none detected. Results are representative of 
4 independent trials. 
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enhanced IL-6 production and dramatically decreased MCP-I production as compared to 
placebo (Fig. II b). Unlike TAMs, TIMs consistently failed to produce IL-I 0 in response 
to LPS stimulation in these studies (Fig. 11 b). We attributed the differences observed in 
cytokine production by TIMs and TAMs to differences in the tissue environments from 
which they were purified. 
IL-t2 induces release oflL-iS in tumor bearing mice. 
Analysis of TAMs from the spleen, lung, and peritoneal cavity ex vivo for 
cytokine gene expression corroborated previous reports that genes for MIF and TGFp 
were significantly elevated (Fig.12a ) 5,33,36, 88, 89. Within 90 min after IL-12 treatment in 
vivo, the splenic, lung, and peritoneal TAMs displayed almost a complete abrogation of 
expression of MIF and TGFp mRNA. This sharp down-regulation of tumor-supportive 
TGFp and MIF gene expression was accompanied by a greater than 10 fold increase in 
expression of IL-15 and IL-18 mRNA relative to placebo (Fig.12b ). Therefore, the same 
impact ofIL-12 on expression of these 4 cytokine genes by TAMs was observed both in 
vitro (Fig. 8) and in vivo (Fig. 12a,b). IL-15 administration to tumor bearing mice has 
been reported to rescue anergic/tolerant tumor-specific cytotoxic T cells. The dramatic 
IL-12 mediated up regulation ofIL-15 gene expression (Fig. 12b) was therefore of 
particular interest. To determine if IL-15 protein was being released as a result of IL-12 
treatment, a blood sample was obtained from mice 2-24 h after IL-12 treatment. Analysis 
revealed that 3 h after IL-12 treatment there was a rapid appearance of IL-15 in the serum 
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Figure 12. IL-12 injection induces a decrease in pro-tumorigenic and an increase in pro-
immunogenic cytokine genes. Peritoneal, lung, and splenic macrophages were purified 
from normal or tumor bearing mice 90 min after IL-12 injection. The cells were 
immediately lysed for mRNA isolation jur qrt-PCR to assay a) pro-tumorigenic MIF and 
TGFb and b) pro-immunogenic genes IL-18 and IL-1S. Data are expressed as ng of 
mRNAl106 cells + s.d. of3 mice, * p <0.05, ** P <0.01. N.d. = none detected. Groups 
compare normal macrophages vs TAMs and TAMs + placebo treatment vs TAMs + IL-
12 treatment. 
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normal mice treated with IL-I2 (Fig. 13a). The contribution of TAMs to this IL-I5 
release was investigated by collecting peritoneal macrophages before and after IL-I2 
treatment and analyzing for the level of cytoplasmic IL-I5. IL-I2 treatment of normal 
mice induced an increase in cytoplasmic IL-I5 in a small fraction of the macrophages 
whereas IL-12 treatment of tumor bearing mice resulted in nearly a complete depletion of 
cytoplasmic IL-I5 (Fig. I3b,c). IL-I5 appeared to be released rapidly as a bolus reaching 
maximum concentration in the serum around 3-4 hrs after IL-I2 injection which 
corresponded to a complete depletion of cytoplasmic IL-15 (Fig. 13b,c ). Serum IL-15 
also disappeared rapidly, as the cytokine was undetectable in the serum 24 hrs after IL-12 
treatment. Macrophage intracellular IL-I5 which was decreased at 2-3 hours after IL-12 
treatment was vastly increased by 18-24 hours after IL-12 injection (Fig 14). 
Activated macrophages from tumor animals aid in the initiation of immuno-
activation in response to IL-12 treatment. 
To determine if the IL-12 induced release of intracellular IL-15 played a 
role in IL-12 initiation of a tumor destructive response, anti-IL-15 or an IgG isotype 
control was injected into tumor bearing mice 1 hr prior to intra-tumor injection ofIL-12. 
Lymphocyte infiltration into the tumor and metastatic lung tissue were then measured 3 
and 5 days later by flow cytometry, and the size and integrity of the primary tumor mass 
and extent oflung metastasis were assessed 10 days post IL-12 injection. Five days after 
IL-12 injection there was a 10 fold increase in infiltrating CD4+ and CD8+ T cells within 
the primary tumor. This increase was not observed in mice treated with 
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Figure 13. TAMs release IL-15 in vivo in response to IL-12 treatment. a) A blood 
sample was collected from normal or tumor bearing mice 3 hrs post IL-12 
injection. Serum IL-15 was assayed by ELISA. Data is displayed as mean ± s.d. of 3 
mice. p=0.012 for normal versus tumor-bearing IL-12 treated mice. n.d.= none 
detected. Results are representative of 2 independent trials (b) Peritoneal M<I>s from 
normal (left panel) or tumor bearing (right panel) mice were analyzed for cytoplasmic 
IL-15 3hrs after IL-12 injection. Specificity was controlled by pre-labeling with cold 
anti-IL-15. c) Mean fluorescence intensity displayed a significant shift in the TAM IL-12 
treated group compared to the normal M<I> treated group. Data are displayed as mean ± 
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Figure 14. TAM cytoplasmic IL-15 is released rapidly as a bolus within 2-3 hrs and is 
replenished by 24 hrs after IL-12 treatment. a) Macrophages from tumor bearing mice 
were purified from peritoneal lavage before or 2-24 hrs after IL-12 injection and stained 
for intracellular IL-15. Specificity was controlled by pre-labeling with cold anti-IL-15. b) 
A blood sample was taken to measure serum levels of IL-15 by ELISA at time points 0, 
3, 12,24, and 48 hrs after IL-12 injection. Data is representative of2 independent trials. 
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anti-IL-IS + IL-12 (Fig. IS). By 10 days post IL-12 injection the tumor volume and 
tumor mass were significantly reduced in the IL-12 treated and IL-12 + isotype control 
treated groups in comparison to the untreated control group (Fig. 16a). In the IL-12 
treated and IL-12 + isotype control treated groups the tumor masses were visibly 
ulcerated (Fig. 16b) whereas there was no indication of ulceration in the untreated 
controL The volume and mass of the subcutaneous tumor harvested from mice treated 
with anti-IL-IS + IL-12 were similar to untreated control group, the anti-IL-IS + IL-12 
group did not display visible signs of ulceration (Fig.16b). Furthermore, an H&E stain of 
cross sections of the primary tumor mass show both infiltration of lymphocytes and as 
well as the breakdown of the tumor stroma in the IL-12 and IL-12 + isotype control 
groups, but not in the untreated control or the anti-ILlS + IL-12 treated groups(Fig. 16c). 
Similarly, metastatic lungs harvested from mice treated with IL-12 displayed a significant 
infiltration of CD4+ and CD8+ T cells and contained dramatically reduced frequency and 
size of metastases (Fig. 17). The lungs harvested from mice treated with anti-IL-IS + IL-
12 displayed very little lymphocytic infiltration and displayed increased frequency and 
size of metastatic lesions compared to the group treated with IL-12 alone (Fig. 18). 
However, the lungs of anti-IL-IS treated mice did not display as extensive metastatic 
tumor growth as the untreated control mice. When these experiments examining IL-12 
induced tumor and metastasis destruction were carried out for longer period of time, mice 
receiving IL-12 treatment had an 80% survival rate up to 30 days post IL-12 treatment at 
which point the untreated control group or animals lacking IL-lS, IL-IS-/- mice or where 
release of IL-IS was neutralized in wild type CS7BLl6 mice, had expired. 
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Figure 15. Neutralization ofIL-15 reduces T cell infiltration in response to IL-12. Tumor 
bearing mice were injected with placebo or IL-12 encapsulated microspheres. One group 
was injected with 250 ng anti-IL-15, Ihr prior to IL-12 treatment. The tumor mass was 
then harvested and analyzed for infiltrating cells 3 and 5 days after IL-12 injection. Data 
are expressed as the mean ± s.d. of 5 mice per group, * p < 0.05 comparing control group 
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Figure 16. Neutralizing IL-15 prevents IL-12 induced tumor destruction. Tumor bearing 
mice were injected with placebo or IL-12 encapsulated microspheres. One group was 
injected with 250 ng anti-IL-15, Ihr prior to IL-12 treatment. The tumor mass was then 
harvested 10 days post injection for analysis. a) Tumor volume was measured using 
bisecting calipers and wet weights were acquired for comparison of the groups. Data are 
displayed as mean weight ± s.d. of 5 mice. b) Tumor ulceration shown by comparison of 
digital images, c) H&E stains from tumor cross sections were performed by University of 
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Figure 17. Neutralization of IL-15 reduces T cell infiltration into metastatic tissue in 
response to IL-12 treatment. Tumor bearing mice were injected with placebo or IL-12 
encapSUlated microspheres. One group was injected with 250 ng anti-IL-15, lhr prior to 
IL-12 treatment. The lungs were then harvested and analyzed for infiltrating cells 3 and 5 
days after IL-12 injection. Data are expressed as the mean ± s.d. of 5 mice per group, * p 
< 0.05 comparing control group or anti-ILl 5 group to IL-12 or IL-12 + isotype control 
treated groups. Results represent 2 independent trials. 
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Figure 18. IL-15 neutralization prevented the clearance of tumor metastasis in the lung. 
Tumor bearing mice were injected with placebo or IL-12 encapsulated microspheres. 
One group was injected with 250 ng anti-IL-I5, 1hr prior to IL-12 treatment. The lungs 
were then harvested and analyzed 10 days after IL-12 injection for size and number of 
metastatic lesions. a) The number of lesions were counted as shown in digital image, b) 
cross sections of the lung were scanned to visualize extent of metastasis, c) an H&E stain 
was done by University of Louisville Pathology Dept, to determine extent of metastasis, 
hemorrhage and lymphocyte infiltration. Similar results were observed in each of 5 mice 
per group. 
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In addition to stimulating an anti-tumor immune response, IL-I2 treatment 
may also be effective in the break -down of the vascular network supporting the tumor. 
Upon examination ofIL-I2 induction of the breakdown of the tumor stroma, we observed 
that tumor bearing animals treated with IL-I2 displayed a dramatic reduction in size of 
the main blood vessel nourishing the tumor or appeared to be absent in many of the IL-I2 
treated mice. However, mice injected with neutralizing anti-IL-IS prior to IL-I2 
treatment were comparable to untreated control mice in that the major tumor blood vessel 
remained exuberant (Fig. 19). 
Macrophages in the tumor microenvironment are activated by cell contact with 
tumor cells and tumor exosomes. 
IL-I2 treatment induces both production of inflammatory cytokines as well 
as release of intracellular IL-IS. However, while IL-I2 can modulate macrophage 
function, it can not effectively activate macrophages. Therefore, macrophages that 
responded to IL-I2 injection presumably received an activating stimulus from some other 
source, e.g.NK cells that were activated in response to the IL-I2 treatment, the 
combination of tumor produced cytokines or cell contact with the tumor. 
To determine whether NK cells activated by IL-I2 were responsible for 
stimulating macrophage activation, macrophages were harvested from beige mice, which 
are reported to lack functional NK cells, bearing a subcutaneous tumor or tumor free 
mice. Cytokine production and gene expression were then measured by cytokine bead 
array (CBA) or qRT-PCR. Cytokine production TNFa, MCP-I, IL-IO and IL-6 
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Control IL-12 
Anti-ILl5 + IL-12 IgG isotype control + lL- I 2 
Figure 19. IL-12 treatment prevents formation or induces the break-down of the major 
tumor blood vessel, which is prevented upon neutralization of IL-15. Tumor bearing mice 
were i~ected with placebo or IL-12 encapsulated micro spheres. One group was injected 
with 250 ng anti-IL-15, Ihr prior to IL-12 treatment. Mice were euthanized 10 days after 
IL-12 treatment for analysis of destruction of the tumor and metastasis. Images of the 
tumor blood vessel are representative of 5 mice per group. 
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were elevated in beige TAMs compared to macrophages from tumor free beige mice upon 
LPS stimulation. However, TAM production of IL-6 and TNFa. was further amplified 
after 1L-12 injection and IL-IO and MCP-I cytokine production was reduced compared to 
placebo treated. Additionally, cytokine genes MIF and TGFp where found to be up-
regulated in beige TAMs but were significantly reduced upon 1L-12 treatment. 
Furthermore, pro-inflammatory IL-15 mRNA was dramatically increased in response to 
IL-12 in both normal macrophage and TAMs (Fig. 20). In addition to mRNA expression, 
IL-15 protein was measured at ng levels in the serum of tumor bearing beige mice after 
treatment with 1L-12, indicating activated NK cells are not essential for activation of 
macrophage cytokine production in the initiation phase of the IL-12 induced anti-tumor 
response. To confirm that macrophage release oflL-15 in response to 1L-12 treatment 
could continue to contributed to the observed CD45+/CD8+ lymphocyte infiltration in 
the absence ofNK cells, NK cells were depleted from normal and beige mice by anti-
NKI.I 24 hrs prior to 1L-12 treatment, additionally to one group neutralizing anti-IL-15 
was administered I hr prior to IL-12 injection. Depleting NKI.I + cells did not inhibit 
CD8+ T cell infiltration in response to 1L-12 induced IL-15 release. Infiltration was 
actually slightly increased in the tumor in the absence ofNK cells (Fig.2I). 
The demonstrations that 1) IL-12 does not activate expression of function 
in normal resting macrophages, 2) that 1L-12 does induce strong inflammatory functions 
in TIMs and TAMs and 3) that NK cells are not essential to the activation ofTIMs and 
TAMs, suggests that TIMs and TAMs were activated prior to IL-12 treatment. Several 
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Figure 20. Macrophages in beige mice respond to IL-12 treatment. Macrophages were 
harvested from the spleen of tumor bearing beige mice before or 3 hours post IL-12 
injection. Cells were either a) plated for analysis ofTNFa, MCP-I, IL-IO and IL-6 
cytokine production in response to LPS or b) lysed immediately for mRNA extraction to 
assay cytokine gene expression by qrt-PCR. c) A blood sample was also taken to 
measure serum IL-15 levels by ELISA. Results are displayed as mean ± s.d. of 3 mice. 
Cytokines TNFa, MCP-l, IL-IO and IL-6 are from a single trial of3 separate mice, Gene 
expression ofMIF, TGF(3, and IL-15 are representative of3 independent trials of3 
separate mice, and serum IL-15 levels are representative of 2 independent trials of 3 
separate mice. 
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Figure 21. Depleting NK cells does not inhibit T cell infiltration in response to IL-12 
induced IL-15 release. Tumor bearing beige (a,c) or tumor bearing wild type (b,d) were 
depleted ofNK cells by injection of anti-NKl.l 24 hrs prior to IL-12 treatment. Anti-IL-
15 was injected 1 hr prior to IL-12 injection. The tumors (a,b) and lungs (c,d) were 
harvested 5 days after IL-12 treatment to analyze infiltrating CD8+ T cells. Percentages 
displayed are based on percent of CD45+. Results are representative of 2 independent 
trials of 4 mice per group. 
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express functions which promote angiogenesis and tumor growth. The mechanism of 
this activation, especially of the tumor-distal TAMs remains unresolved 26,31,32,35,36,48. To 
corroborate that macrophages were in as activated state in vivo in the 3LLC model, TIMs 
and TAMs were purified from the primary tumor mass, or from the spleen, peritoneal 
cavity, and lung tissue of mice bearing subcutaneous 3LLC tumors and lung metastasis. 
The macrophages were plated for 17 hrs without exogenous stimulation after which the 
cultures were assayed for cytokine accumulation. TAMs from the spleen, peritoneal 
lavage, and the lung produced 2-16 times more TNFa, MCP-1, IL-lO, and IL-6 than 
macrophages from normal healthy tissues. TIMs also produced elevated levels of TNF a, 
MCP-1, and IL-6 but did not produce detectable levels ofIL-lO (Fig.22a). These results 
were confirmed in other lung carcinoma models, LL2 and TC-1, indicating that 
macrophages are activated in the presence of a tumor and the results observed were not 
unique to the 3LLC carcinoma (Fig.22b). 
To determine whether cytokines or other soluble factors released by the 
tumor were responsible for macrophage activation in situ, macrophages from normal 
mice were cultured in vitro with the filtered supernatant from primary 3LLC tumor cell 
cultures. The 3LLC supernatant contained high levels ofMCP-1, VEGF, and TGFp. 
Cytokine analysis did not reveal evidence of macrophage activation with the exception of 
pro-MMP-9, which has been shown to be released in response to high levels ofVEGF 35, 
37. However, culturing the macrophages in unfiltered tumor supernatant clearly resulted 
in activation as measured by an increase in production ofTNFa, MCP-1, IL-lO, IL-6, 
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Figure 22 - TAMs are actively producing cytokines upon ex vivo analysis. M<l> were 
6 
purified from the primary 3LLC tumor, peritoneal lavage, spleen, and lungs of normal or 
mice bearing a 0.6cc tumor with lung metastasis .. (a) TIMs and TAMs were plated 
overnight with no further stimulation for 17 hours to allow for cytokine accumulation. 
Supernatants were then harvested and a')sayed by CBA. (b) TAMs from various tumor 
models were harvested and assayed for cytokine production. Data represented as mean + 
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Figure 23. Unfiltered tumor supernatant activated macrophages. Normal peritoneal 
Mc:I>s were cultured overnight with filtered (O.2~) or unfiltered supernatants of 3LLC 
tumors passaged one day ex vivo. The culture supernatants were assayed for cytokines. 
Data is expressed as mean + s.d. of triplicate cultures. n.d. = none detected. Results are 
representative of 5 independent trials. 
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exosomes of the tumor membrane expressing tumor cell surface molecules 54. The 
exosomes are thought to contribute to the systemic suppression of the immune system as 
well as in tumor metastatic development 54,55,90,91. This led us to consider the possibility 
that exosomes in the unfiltered tumor culture supernatant could activate macrophages 
upon cell contact. To determine whether exosomes released by the tumor were capable 
of activating macrophages, exosomes were purified by magnetic bead selection using a 
tumor specific hMuc-l Ab and were cultured with macrophages for 17 hrs. ELISA and 
CBA analysis confirmed that normal peritoneal macrophages cultured with exosomes 
produced elevated levels of1NFu, MCP-l, IL-lO, IL-6, VEGF, and pro-MMP-9 (Fig.24). 
Tumor cell and macrophage interactions occur through CD40/CD154 and 
NKG2DlRae-1. 
Previous studies on many types of cancer reported that tumor cells 
express activation receptors and their corresponding ligands such as CD40 ICD 154 and 
NKG2DlRae-1 20,53,56,92,93. We have confirmed that these ligands are expressed by 
3LLC ex vivo (Fig 25). Macrophages are known to be activated by ligation ofCD40 12,57 
and macrophages purified from tumor bearing mice displayed elevated expression of 
CD40 compared to macrophages from tumor-free mice (Fig.25). Analysis of 
macrophage surface expression ofNKG2D produced varying results when assayed by 
flow cytometry, 3 trials indicated elevated NKG2D surface expression on peritoneal 
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Figure 24. Tumor exosomes activate M<l>s. Normal peritoneal M<l>s were cultured 
overnight with exosomes purified by magnetic bead selection ofhMuc-l + particles in 
unfiltered supernatants of cultures of hMuc-l transfected 3LLC tumor cells. Data are 
expressed as mean ± s.d. of triplicate cultures. Results are representative of 4 independent 
trials. 
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Figure 25. Tumor cells express CD40L and Rae-I and TAMs but not normal M<l> 
express elevated levels of surface CD40 and NKG2D receptors. 3LLC as determined by 
hMuc-l + population were stained ex vivo for cell surface expression with fluorescent 
Abs to CD40L (CDl54) and Rae-I. M<l>s as determined by the Mac-l + (CDIlb) 
population were stained ex vivo for cell surface expression of CD40 and NKG2D. 
Staining for NKI.I was used as a control to verify populations were free ofNK 
contamination. Results are representative of 3 independent trials. 
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TAMs in comparison to nonnal peritoneal macrophages, while 2 trials displayed only 
background staining levels. The data was even more disconcerting by the observation 
that both TAM and nonnal macrophages from lung tissue stained positive for NKG2D 
surface expression, by others in our lab (data not shown). However the presence of 
NKG2D mRNA was observed in both TAM and nonnal macrophages by qrt-PCR, 
NKG2D gene expression was observed to be up-regulated by a factor of 78 in peritoneal 
TAMs in comparison to nonnal peritoneal macrophages and up-regulated by a factor of 
32 compared to nonnal resting NK cells purified from a spleen of a healthy animal 
(Fig.26). Interestingly, nonnal peritoneal macrophages cultured for 24 hrs in the 
presence of3LLC exosomes and culture supernatant displayed increased NKG2D gene 
expression in comparison to nonnal macrophages cultured without exosomes (Fig. 26). 
To detennine whether 3LLC exosomes were activating macrophages by ligation of CD40 
or NKG2D, nonnal peritoneal macrophages were stimulated with 3LLC exosomes in the 
presence or absence of blocking anti-CD I 54 and/or anti-NKG2D. Blocking either 
CDl54 or NKG2D significantly reduced exosome induced TNFu, IL-lO, IL-6, and pro-
MMP-9 production. Blocking both NKG2D and CD40 ligation completely abrogated 
cytokine release including MCP-l, which was not significantly affected by blocking only 
one receptor ligand interaction (Fig 27). A titration of the Abs shows a dose dependant 
response when added separately, but total blockage of cytokine production or release 
when added in combination (Fig. 28). To insure specific blocking by anti-NKG2D, 
rmNKG2D-Fc was added to the cultures. The addition ofrmNKG2D-Fc prevented 
inhibition of cytokine production by anti-NKG2D (Fig 29). Further analysis revealed 
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Figure 26. TAMs express elevated NKG2D gene expression. Macrophages were 
harvested from normal or tumor bearing mice and lysed for mRNA extract immediately 
or normal macrophages were plated with exosomes for 24 hrs prior to lysis. NK cells 
were harvested from the spleen of a normal mouse and used as a positive control for 
NKG2D expression. 3LLC tumor cells were also lysed ex vivo for comparison. Results 
are representative of 4 independent trials. 
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Figure 27. CD40 and NKG2D are involved in macrophage activation by tumor 
exosomes. Macrophages were purified from the peritoneal lavage of normal animals and 
cultured for 17 hrs with 3LLC exosomes in the presence or absence of blocking Abs to 
NKG2D and CD 154. The supernatants were then harvested and analyzed for cytokine 
production by CBA and ELISA. Results are displayed as mean ± s.d. of triplicate 
cultures. *p<0.05 comparing un-stimulated vs exosome stimulated and exosome 
stimulated vs exosome stimulated in the presence of blocking Abs. Results are 
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Figure 28. Blockade of either NKG2D or CD40 ligation interferes with exosome 
activation ofMF. The combined inhibition of ligation of both CD40 and NKG2D was 
synergistic and completely abrogated the response ofMF to 3LLC exosomes. Normal 
peritoneal M<D were plated in the presence or absence of3LLC exosomes in increasing 
concentrations of anti-NKG2D and/or anti-CD 154 Ab separately or in combination for 17 
hrs. Culture supernatants were then harvested and analyzed by ELISA for cytokine 
production. Results are displayed as mean ± s.d. of triplicate cultures and representative 
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Figure 29. Anti-NKG2D Ab specifically blocks macrophage activation by exosome 
NKG2D ligation as shown Fc-rmNKG2D inhibited the ability of the blocking antibody to 
prevent cytokine production. Peritoneal macrophages were purified from (a) normal 
animals or (b) tumor bearing animals and cultured for 17 hrs with 3LLC exosomes in the 
presence or absence of blocking anti-NKG2D or Fc-rmNKG2D + anti-NKG2D. The 
supernatants were then harvested and assayed by ELISA. Data are displayed as mean ± 
s.d. of triplicate cultures. The results are representative of 2 independent trials. 
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CD40-/- macrophages cultured with exosomes for 17 hrs were activated as measured by 
macrophage cytokine production. CD40-/- macrophages stimulated with exosomes were 
observed to produce substantial levels ofMCP-I, IL-6, and pro-MMP-9 production in 
comparison to un-stimulated macrophages, but they produced significantly less TNFu, 
MCP-l, IL-I 0, IL-6, and pro-MMP-9 than wild type macrophages stimulated with 
exosomes (Fig.30). In addition blocking NKG2D in CD40-/- macrophages completely 
abrogated TNFu, MCP-I, IL-I 0, IL-6,and pro-MMP-9 production and/or release (Fig. 
30). As a control it was shown that blocking Abs for NKG2D and CD154 did not prevent 
macrophage activation of cytokine production in response to LPS stimulation (Fig 31). 
CD40 is essential for metastatic growth. 
Macrophages have been shown to be important for tumor metastatic 
capabilities. They have been referred to as the mediators of the angiogenic switch in 
tumorigenesis by providing many cytokines and growth factors important for tumor 
escape and metastasis, particularly VEGF and MMP-9 26,30,37,94. Therefore to determine 
whether the failure of macrophage activation by CD40 ligation in vivo altered the 
activities of TAMs or tumor cells, 3LLC tumor cells were injected subcutaneously into 
wild type or CD40-/- mice and macrophages were harvested when the tumors were 
approaching 0.5cc to assay for cytokine production. Production ofTNFu, MCP-l, IL-lO, 
and IL-6 were greatly decreased in the TAMs from CD40-/- animals compared to wild 
type TAMs (Fig.32). Interestingly, even the release of intracellular IL-15 upon exosome 
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Figure 30. CD40 and NKG2D are involved in macrophage activation by tumor 
600 
exosomes. Peritoneal M<l>s from normal or CD40-/- mice were cultured overnight with 
3LLC exosomes in the presence or absence of neutralizing anti-NKG2D. The culture 
supernatants were assayed for cytokines by CBA and ELISA for MMP-9. Data are 
expressed as mean ± s.d. of triplicate cultures * p <0.05 comparing groups WT M<l>s vs 
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Figure 31. Blocking Abs to NKG2D and CD 154 do not inhibit macrophage cytokine 
production in response to LPS stimulation. Macrophages were purified by bead selection 
from peritoneal lavage of normal mice. Cells were then stimulated with LPS or 3LLC 
exosomes in the presence or absence ofanti-NKG2D and anti-CD154 blocking Abs for 
17 hrs. The supernatants were then harvested and assayed by ELISA to detect cytokine 
production. Results are displayed as mean ± s.d. of triplicate cultures. Results are 
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Figure 32. Cytokine secretion is decreased in TAMs from CD40-/- tumor bearing mice. 
Peritoneal M<l>s were purified from peritoneal lavage of wild type and CD40-/- tumor 
bearing mice and cultured overnight without stimulus to allow for cytokine accumulation. 
The supernatants were analyzed for cytokines by CBA. Data are expressed as mean ± s.d. 
for 3 mice per group. *p<O.05 comparing groups wild type TAMs vs CD40-/- TAMs. 
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Figure 33. Tumor activated macrophage IL-15 release is blocked in the absence ofCD40 
and/or NKG2D ligation. Wild type or CD40 -/- peritoneal macrophages were cultured for 
2 hrs with exosomes + 5nglml IL-12 in the presence or absence ofanti-NKG2D. IL-15 
was assayed by ELISA. Data represented as mean + s.d. n = 3 mice, p= 0.001 for 
anti-NKG2D vs. wild type control, p = 0.0008 for CD40-/- vs. wild type control, and 
p = 0.0001 for CD40-/- + anti-NKG2D vs. wild type control. n.d. = no cytokine detected. 
Data representative of 2 independent trials. 
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and IL-12 stimulation was blocked in the absence of functional CD40 or upon the 
addition of anti-NKG2D blocking Ab (Fig. 33). Conversely, although cytokine 
production and release by TAMs was inhibited in CD40-/- mice, growth of the primary 
tumor mass appeared to be more rapid. However, further observations revealed that 
unlike wild type animals there were no metastatic lesions in the lung tissue ofCD40-/-
mice (Fig. 34), coinciding with a significant decrease in pro-MMP-9 and VEGF 
production by TAMs from CD40-/- animals (Fig. 35). 
TAMs stimulate tumor cells via CD40/CD154 interaction. 
The reduction in cytokine production was observed not only in the CD40-
/- TAMs, but was also significantly decreased in tumor cells harvested from CD40-/-
animals in comparison to wild type mice (Fig.36). To determine whether this effect was 
due at least in part to reduced interaction with macrophages, the stability of tumor 
phenotype, which contributes to macrophage activation, was examined by flow 
cytometry. We observe that, 3LLC phenotype is not constitutive, but when cultured in 
vitro in the absence of the tumor stroma as well as the absence of macrophages or 
macrophage produced tumor supportive cytokines, the expression of surface receptors 
and ligands recedes (Fig.37a and Table I). However, adding TAMs, but not normal 
macrophages, to cultures sustained or restored tumor expression of surface molecules, 
CD40, CDI54,NKG2D, CD44, IL-15RP, Rae-I, and H2Kb (Fig.37b and Table I). TAM 
support of tumor phenotype appeared to be dependent on several receptor ligand 




Figure 34. CD40-/- tumor bearing animals displayed reduced lung metastasis in 
comparison to tumor bearing wild type mice. Mice bearing O.5cc subcutaneous tumors 
were sacrificed and purfused for lung extraction. The lungs were then sent to the 
University of Louisville Pathology Dept. for sectioning and an H&E staining. Cross 
sections were then scanned and digital pictures were taken at lOx magnification. Images 
are representative of 3 mice per group. 
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Figure 35. CD40-/- TAMs produce reduced levels ofMMP-9 and VEGF in comparison 
to wild type TAMs. Peritoneal M<1>s were purified from peritoneal lavage of wild type 
and CD40-/- tumor bearing mice. The cells were then cultured overnight without 
stimulus to allow for ELISA. Data are expressed as mean ± s.d. for 3 mice per group. 
*p<0.05 comparing groups wild type TAMs vs CD40-/- TAMs. Results are 
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Figure 36. Tumors grown in CD40-/- mice produce significant amounts of angiogenic 
factors MMP-9 and VEGF, although drastically less than tumors grown in wild type 
mice. Tumors approaching O.5cc were harvested from wild type or CD40-/- mice, made 
into single cell suspension and 3LLCs were purified by hMuc-l Ab and magnetic beads. 
The cells were then plated for 17 hours to allow for cytokine accumulation without 
stimulus. The supernatants were then assayed by ELISA. Data are displayed as mean ± 
s.d. of triplicate cultures from 3 separate mice. *p<O.05 comparing tumors from WT mice 
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Figure 3 7 - TAMs restore tumor expression of surface molecules. Tumors were harvested 
and stained for the presence of CD 154, CD40, IL-15Rb and Rae-l ex vivo, after 3 in vitro 
passages and after 3 in vitro passages with TAMs added for the last 24 hrs. Results are 
representative of 4 independent trials. 
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3LLC ex vivo pass x 2. WT CD40KO IL-'15KO 
r- C640--- 70.4 ----'-----.f4-:-- -9i8 ---+- 6.3 28.9 
CD154 63.6 4.5 67.8 1.4 28.9 
CD44 148.2 136.5; 325.9 1430.8 422.7 
---'Rae:1--42:9---27--:--79:s---- 93.7 -----'67:-1-
NKG2D 51.7 6.6: 338.4 ' 20.4 ' 1:26.5 
IL-15Rb 320.1 7.3 I' 456.7 10.2 iJ:t-
H2Kb 26.5 19.5 317.7 2.65 413.02 
B16F10 ex vivo pass x 2 WT 
CD40 . 11.81 
__ 9.5~ __ 11.09 -----~-------------' 
--9.06-CD154 8.83 3.78 
CD44 500.7 190.4 3164.8 
Rae-1 56.4 8.9 63.7 
NKG2D 62.9 36.9 65.1 
IL-15Rb 98.4 13.8 609.4 
----------------1 -----"-~-
------
H2Kb 59.5 28.5 144.9 
TC-1 ex vivo pass x 2 WT 
CD40 159.6 43.5 107.1 
--C[)154 ---~1--·-·'-To~T--- '--74:4-
CD44 706.2 73.06 1458,1 
Rae-1 22.9 3,5 32.6 
NKG2D 28.7 6.18 44.8 TL-f5Rb'---'--i~8--'-' ·-:2:"5-·---- -- --;(81'--
H2Kb 40.9 3.5 136.7 
Table 1. Tumor - macrophage interactions dependent on many receptor ligand 
interactions, wild type TAMs, but not CD40-/- or IL-IS-/- TAMs restore various tumors 
phenotype. Tumors were harvested and stained for the presence of CD40, CD1S4, CD44, 
Rae-I, NKG2D, IL-1SRb, and H2Kb ex vivo, after 2 in vitro passages and after 2 in vitro 
passages with TAMs from WT, CD40-/- and IL-IS-/- mice added for the last 24 hrs. Data 
are displayed as mean fluorescence intensities (MFls). Results are representative of2 
independent trials. 
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restore 3LLC expression of CD44 and Rae-l but were not able to restore 3LLC expression 
of CD 40, CD154, NKG2D, IL-15R~, or H2Kb. In contrast, TAMs from IL- 15-/- mice 
effectively restored expression ofCD44, NKG2D, and H2Kb, but not CD40, CD154, Rae-
1 or IL-15R~. In addition to surface molecule expression 3LLC cytokine production and 
gene expression was also greatly reduced with each in vitro passage (Fig.38). However, 
cytokine production and gene expression was restored or in some instances increased 
when 3LLCs and TAMs were co-cultured overnight (Fig 38). This apparent symbiotic 
relationship between TAMs and tumor cells held true for other carcinoma cell lines, such 
as LL-2 and TC-l and to a smaller degree the Bl6FI melanoma (Fig. 38). 
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Figure 38. Tumor cytokine production induced by TAMs. Tumors were harvested and 
lysed for mRNA extraction for qr-PCR analysis ex vivo, after 3 in vitro passages and after 
3 in vitro passages with TAMs added for the last 24 hrs, the cells were then separated prior 
to lysis by magnetic beads. Data are displayed as ngll 06 cell mRNA and mean ± s.d. of 
triplicate cultures and 3 individual mice. *p<0.05 comparing ex vivo tumor cells vs in 
vitro passaged tumor cells or passaged tumor cells vs passaged tumor cells + TAMs. 
Results are representative of 3 independent trials. Results were confirmed in TC-l 
carcinoma and B 16F 1 melanoma. 
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DISCUSSION 
Macrophages display an array of diverse functions which are differentially 
expressed based on response modifiers present in the environment. TAM function is a 
prime example of functional plasticity, as tumor produced metabolites alter macrophage 
functional properties toward tumor supportive. Tumor cells employ a number of 
mechanisms to prevent detection and destruction by the immune system. Mechanisms 
including, the down regulation of HLA class I expression on their surface, the absence of 
co-stimulatory molecules on tumor cells, which reduces the ability of the adaptive immune 
response to detect the tumor, and the production of cytokines and growth factors, which 
further promotes an anti-inflammatory environment 19,20,28,42, 53,95,96. These mechanisms 
can directly act on cells of the immune system by preventing their activation, for example, 
Ag processing is decreased on class I and class II MHC, NK cytotoxic activity, IFNy 
production and NKG2D expression are down regulated, and there is a significant increase 
in the number of regulatory T cells 28,67,97,98. The tumor and the suppressive tumor 
environment contributes to the altered functional phenotype and activities of macrophages 
1,5,45,96. Macrophages within the tumor contribute to tumor growth by the production of 
pro-tumorigenic factors as shown in figure 7 and macrophages distal to the tumor mass 
also produce pro-tumorigenic cytokines and growth factors as shown in figures 5, 7, 11, 
and 12. Tumor infiltrating and tumor associated macrophages, as shown here, are 
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modulated by tumor produced cytokines, but are likely to receive the activation stimulus 
by cell contact with tumor cells or tumor exosomes. 
Exosomes can bind to cells and mediate different biological functions. 
They were first observed to be biologically active in 1996 when B cell derived exosomes 
were shown to induce Ag specific MHC class II restricted T cell responses and also in 
1998 in a report where DC derived exosomes were shown to induce tumor eradication 99-
101 _ There is evidence of interaction between tumor derived exosomes and APCs. In 
addition to ligands, most tumor derived exosomes also have enriched heat shock proteins 
(HSPs), which are believed to increase interaction or uptake by APCs 50,51. The exosome / 
APC interaction was shown to induce stimulation of an immune response, mice were 
injected with a single dose of plasmocytoma cell derived exosomes, and were then 
challenged by injection of wild type tumors. The mice undergoing challenge generated 
specific cytotoxic T cells with tumor specific immunity and were protected from tumor 
development 50-52. 
The functions that an exosome can mediate will be highly dependent on 
the surface proteins expressed. The surface complexes of exosomes include ligands to 
various cell surface receptors, which can mediate interactions between two cells. In the 
case of the 3LLC model used in this study, tumor cells and tumor exosomes were observed 
to be able to activate macrophages by ligation of CD40 and/or NKG2D as evidenced by 1) 
the activation of macrophages from culture with tumor released exosomes, shown in 
figures 21 and 22" 2) the inhibition of activation, shown in figures 25 and 26, by anti-
CD154 and/or anti-NKG2D, and 3) by the attenuated activation stimulation of ex vivo 
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TIMs and TAMs from tumor bearing CD40-/- mice along with the reduced responsiveness 
of CD40-/- macrophages stimulated with exosomes as shown in figures 27 and 28. 
Taking a closer look at the impact ofCD40 deficiency on tumor growth and 
macrophage activation, we observed a vast difference in the activation of both TAMs and 
tumor cells from CD40-/- tumor bearing mice. TAMs from these animals produced 
significantly less cytokines than TAMs harvested from wild type mice bearing tumors 
which were comparable in size to the CD40-/- mice. In addition to reduced macrophage 
activation and cytokine production, CD40-/- tumor bearing mice, were not observed to 
have metastatic lesions on the lung, whereas the lungs of tumor bearing wild type mice 
contained areas of heavy metastases. Application of information from reports 
demonstrating that macrophages are important for metastatic spread 7,20,31, and the data 
herein, which demonstrates that TAMs are not activated in CD40-/- tumor bearing mice, 
and that normal macrophages are not activated by exosomes in the presence of blocking 
anti-CD 154, indicates that there is link between macrophage activation by CD40 ligation 
and tumor progression and the development of metastasis. This connection could 
potentially serve as a target for CD40 driven therapies. Administering an agent such as 
CD154 or anti-CD40 rnAb may disrupt the tumor-macrophage relationship or the 
activation of tumor supportive activities in macrophages by interfering with the 
availability of cell contact interactions through CD40-CDI54. In speculation, the 
disruption of this relationship may relieve some of the effects of the irnrnuno suppressive 
environment on NK, DC and T cells, enabling mobilization of an anti-tumor response. 
Targeting CD40, by treatment with ligands and/or monoclonal Abs has previously been 
attempted, in the aspect of its direct effect on the tumoi9,33, 110. The relevance of CD40 
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expression by tumors is unclear. However, literature indicates that CD40 stimulation on 
tumor cells, results in increased cytokine production by the tumor, most commonly IL-6 
and IL-8 93,114,118. Both of these cytokines are important for angiogenesis and contribute 
to metastatic spread. CD40 activation has been shown to both induce proliferation and 
survival in many tumors, malignancies, and leukemias by inhibiting Fas mediated 
apoptosis, and has also been reported to induce growth arrest and apoptosis in several 
other carcinomas although, through unknown mechanisms 29, 112, 114-117. The observed 
differences in stimulation of tumor cells by CD40 ligation have been attributed to the 
setting in which stimulus was received, for example, prolonged vs. transient stimulation 
and/or soluble CD 154 vs. membrane bound stimulation 29,33,93. The activation of CD40 
has been examined in therapeutic settings by the delivery of soluble CD 154 or anti-CD40 
mAb and/or delivery ofligand through gene therapy. Reports suggest that CD154 therapy 
has shown promising effects, inducing elevated levels of serum IFNy and IL-12 as well as 
inducing a measurable increase in T cell activation, which can specifically recognize and 
destroy tumor cells 33,110,114-116,119. The greatest successes acquiring DC and CD8+ T cell 
responses were attained by combining CD40 ligation with the administration of pro-
inflammatory cytokines IL-12 or IL-2. CD40 stimulation can synergize with IL-2 for anti-
tumor responses, as was shown against mouse metastatic renal cell carcinomas, the 
administration of combined treatment resulted in increase numbers of tumor-specific 
CD8+ T -cells and dendritic cells in both the spleen and liver 6,29, 120, 121. 
In addition to CD40 ligation, in this study, we demonstrate a potential role for 
NKG2D ligation in tumor macrophage activation. NKG2D is an activation receptor, 
typically reported to be preferentially expressed by NK cells and functions, when 
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activated, to allow for the detection and destruction of diseased host cells 53. Furthennore, 
it is a multi subunit receptor complex, and NKG2D signaling is mediated by specialized 
signaling adaptors. Mouse NKG2D can associate with two distinct adaptors, DAP-IO and 
DAP-12, while human NKG2D only associates with DAP-lO 92. NKG2D receptor is 
constitutively expressed on most innate immune effector cells including NK, TCRy3 T 
cells and most NKT cells. NKG2D expression on macrophages is controversial, it was 
first reported by Diefenbach in 2000, but the reports of surface expression have not been 
able to be confinned, although, mRNA expression has been reported several times 20,92,122. 
Interestingly, many reports show that there is functional NKG2D on murine IFN producing 
dendritic cells, which are of myeloid origin 20,92, 123, 124. We demonstrate here that levels of 
NKG2D mRNA gene expression can be up or down regulated in macrophages. High 
NKG2D gene expression is observed in TAM populations and lower expression is 
observed in nonnal macrophages populations, which can also be up-regulated when 
nonnal macrophages are cultured in the presence of3LLC exosomes. This data is in 
opposition to patterns ofNKG2D expression in NK cells. Nonnal NK cells express high 
levels ofNKG2D, whereas NK cells from tumor animals express lower levels ofNKG2D, 
both mRNA as well as protein expression. Ligation ofNKG2D results in surface 
modulation of the receptor and reduced function upon subsequent receptor engagement. 
Thus, chronic exposure to tumor cells expressing ligands to NKG2D alters NKG2D 
signaling in NK cells which facilitates the evasion of tumor cells from NK detection and 
cytotoxic activities 53. 
Another avenue for therapy currently under investigation is cytokine therapy. 
Rather than targeting activation of receptors, our data supports the idea that it may be more 
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beneficial to use the activation provided by the tumor and modulate the functions 
expressed by immune cells through cytokine treatments. TIMs and TAMs appear to be 
both activated and modulated by tumor cells and tumor exosomes, but they maintain a 
high degree of plasticity, they therefore, can continue to be rapidly converted to other 
functional phenotypes by the appropriate cytokine treatment. As we have shown here, 
TIMs and TAMs are observed to be producing tumor supportive cytokines, TGFp, VEGF, 
MIF, MCP-l, and IL-I0, upon ex vivo analysis. However, IL-12 treatment in vitro and in 
vivo rapidly down-regulated or attenuated production of the tumor supportive cytokines 
and concomitantly up-regulated production of pro-immunogenic cytokines, TNFa, IL-6, 
IL-18, and released their store of cytoplasmic IL-15. The rapid change in the functional 
profile suggests three things, 1) IL-12 treatment can effectively overcome the influence of 
the tumor environment and allows the shift of macrophage functions form pro-tumorigenic 
to pro-immunogenic, 2) the shift in macrophage function occurs very rapidly, at least 
within 90 min of IL-12 treatment, and is stable for at least up to 5 days, and 3) the shift in 
TAM phenotype occurred systemically as was observed by analysis of tumor infiltrating, 
peritoneal, lung and splenic macrophages. The importance of this shift in function, is that 
1) macrophages no longer contribute to angiogenesis and tumor growth and 2) it allows for 
a reduction in the immunosuppressive environment, allowing NK and T cells to become 
activated. NK cells have been observed to become activated 3-5 days after IL-12 
treatment and CD8+ CTLs have been observed to be present and activated 5-7 days post 
IL-12 treatment, both of which display cytotoxic activities and producing elevated levels 
of pro-inflammatory cytokines 61,62, 102-104. The activation and pro-inflammatory cytokine 
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production ofNK and CTLs, then drives the anti-tumor response, including the induction 
of cytotoxic and effector activities by the macrophage. 
IL-12 has a strong anti-tumor effect against many cancers including melanomas 
and colon, renal, mammary and ovarian carcinomas 13,60,64. However, enthusiasm for the 
use ofIL-12 as a treatment for human patients, waned when i.v. administration led to 
severe toxicity in phase II trials 95. However, toxicity has been greatly over come in recent 
trials by administering the cytokine by subcutaneous injections or most impressively by 
local delivery to the tumor in encapsulated microspheres, which allows for a slower and 
prolonged release ofIL-12 23,61,103,105. A single dose ofIL-12 has been shown to cause 
elevated levels of IFNy, IL-18, and IL-15 63,96,106. Tumor regression was consistent when 
elevated serum levels of IFNy, IL-18, and IL-15 were maintained. While it has been 
established that NK and T cells respond to IL-12 by increasing production of IFNy, they 
do not produce or release IL-15. Many cells, such as epithelia and other stromal cells, 
reportedly express IL-15 on their membrane, the source of IL-12 induced free IL-15 in the 
serum is unknown. We show here that TAMs rapidly release cytoplasmic IL-15 as a 
bolus, during the peak time point at which IL-15 is observed in the serum, going from 
undetectable to 5-6 ng/ml. This data demonstrates that TAMs are responsible, at least in 
part, for elevated serum IL-15. 
The rapid release of IL-15 from macrophages as well as other stromal cells 
in response to IL-12 treatment seems to playa significant role in the efficacy of IL-12 
treatment, as evidenced by the lack of lymphocyte infiltration into the tumor and 
metastatic lung, as well as the lack of tumor destruction and metastatic clearance when IL-
15 is neutralized or blocked. The data shown in this study, in the reports ofIL-15 being 
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essential to NK survival and activation 76, the demonstration of the essential role ofIL-15 
in the rescue of anergic CD8+ T cells within the suppressive tumor environment 45,75,81,107, 
108 and the observation ofthe ability ofIL-15 to reverse tumor induced inhibition of class I 
MHC processing by DCs indicates that IL-15 is an essential component for effective 
cytokine therapy 58,71,72,74,109. IL-15 is currently being examined as a potential candidate 
for cancer therapies 69, however, IL-15 alone has not been shown to be as efficient as it is 
in combined cytokine therapies 32,61. Our study indicates that TAM release ofIL-15 in 
response to IL-12 is substantial and important to the initiation and promotion of the anti-
tumor response. It is likely that upon release, IL-15 combines, or acts synergistically, 
with the IL-12, as well as other released pro-inflammatory cytokines such as IL-18, IL-21, 
IFNy, etc. to promote the innate and adaptive anti-tumor responses 61,70,84. 
According to literature there seems to be a link between available IL-15 and 
NKG2D expression. IL-15 has been reported to up-regulate both DAP-lO and NKG2D 
expression, as well as prime NKG2D signal transduction by constitutive ERK 
phosphorylation 92, 125-127. However, the mechanism ofthis priming remains elusive. 
Interestingly we observe that macrophage release of IL-15 is inhibited when NKG2D is 
blocked, which further indicates there may be a link between IL-15 and NKG2D 
expression. Smyth et. al. report that neutralization ofNKG2D reversed the efficacy ofIL-
12 treatment 92, 128. This report agrees with our data in two ways, 1) we show that 
neutralization ofNKG2D prevents IL-15 release, and blocking IL-15 prevents lymphocyte 
infiltration into the tumor and lung, and prevents tumor destruction and metastatic 
clearance, and 2) neutralizing NKG2D attenuated production of other pro-inflammatory 
cytokines by macrophages, important for both the initiation and effector phases of the anti-
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tumor response. It is the hope that future investigations into the macrophage-tumor cell 
relationship will lead to better understanding of TAM activation and TAM support of 
tumor phenotype. Understanding of this relationship is likely to provide insight as to the 
mechanisms by which IL-12 induces IL-15 release by TAMs, which currently remains 
elusive, but is clearly an important event for effective cytokine therapy. 
Conclusions 
This study provides insight as to the activation and modulation of TAMs 
by tumor cells, tumor exosomes and tumor produced cytokines. We demonstrate that 
TAMs are not a stable, functional subset of suppressive tumor macrophages, but can 
rather can be rapidly converted to display pro-immunogenic functions by the appropriate 
pro-inflammatory cytokine treatment both in vitro and in vivo. Furthermore, in this 
demonstration we observed that macrophages are responsible, in part, for the initiation 
of an anti-tumor immune response by releasing a bolus of IL-15 upon treatment with IL-
12. IL-15 is important to the mobilization of the NK, CD4+, and CD8+ T cells, as we 
demonstrated by the inhibition of mobilization when IL-15 was blocked during IL-12 
treatment. As an indication of their importance in initiation of anti-tumor responses 
macrophages are capable of responding to IL-12 treatment, decreasing pro-tumorigenic 
cytokine production and increasing pro-immunogenic cytokine production and releasing 
intracellular IL-15, in the absence ofNK cells. These functions occurred at the same rate 
and level whether NK cells were present or absent providing further evidence that TAMs 
are in an activated state, having been previously activated by the tumor, and modulate 
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their function upon lL-12 treatment. Based on this study we hypothesize that it is these 
mechanisms by which lL-12 is an effective treatment agent. Regardless of the therapy, it 
seems to first be necessary to disrupt the immuno subversive activities of the tumor, 
including the disruption of the tumor / macrophage relationship. This disruption 
provides the needed window of opportunity which allows for the generation of an anti-
tumor cytotoxic response, and which could possibly lead to the development of central 
memory for long term tumor immunity. 
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